Novartis to present new clinical trial results for leukemia and advanced breast cancer treatments.

Novartis will present new 96-week results from the Scemblix ASC4FIRST trial at the ASH conference and late-breaking analysis from the Kisqali NATALEE trial at the San Antonio Breast Cancer Symposium. These trials focus on treatments for chronic lymphocytic leukemia and advanced breast cancer, respectively. The findings aim to provide new insights and treatment options for patients with these conditions.

November 25, 2024
4 Articles

Further Reading